Have questions? Visit https://www.reddit.com/r/SNPedia

rs10509681

From SNPedia

Orientationplus
Stabilizedplus
Geno Mag Summary
(C;C) 2 >1.81x risk of GI bleeding with some NSAID drugs
(C;T) 1.5 Increased risk of GI bleeding with NSAIDs
(T;T) 1 No increased risk of GI bleeding on NSAID drugs
ReferenceGRCh38 38.1/142
Chromosome10
Position95038992
GeneCYP2C8
is asnp
is mentioned by
dbSNPrs10509681
dbSNP (old)rs10509681
ClinGenrs10509681
ebirs10509681
HLIrs10509681
Exacrs10509681
Varsomers10509681
Maprs10509681
PheGenIrs10509681
Biobankrs10509681
1000 genomesrs10509681
hgdprs10509681
ensemblrs10509681
gopubmedrs10509681
geneviewrs10509681
scholarrs10509681
googlers10509681
pharmgkbrs10509681
gwascentralrs10509681
openSNPrs10509681
23andMers10509681
23andMe allrs10509681
SNP Nexus

SNPshotrs10509681
SNPdbers10509681
MSV3drs10509681
GWAS Ctlgrs10509681
GMAF0.06474
Max Magnitude2
? (C;C) (C;T) (T;T) 28
GET Evidence
CYP2C8-K399R
aa_change Lys399Arg
aa_change_short K399R
impact pharmacogenetic
qualified_impact Insufficiently evaluated pharmacogenetic
overall_frequency 0.0866332
summary Impaired metabolism of paclitaxel in vitro, lower plasma concentration of repaglinide and rosiglitazone.



This is a CYP2C8 SNP. The CYP2C8*3 allele is mapped to both rs10509681 and rs11572080).

[PMID 19422321] In a 2009 article titled "Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?" It is claimed that individuals carrying minor alleles of this SNP (usually heterozygotes, since minor homozygotes are rare) may show increased risk of developing acute gastrointestinal bleeding during the use of NSAIDs that are CYP2C8 or CYP2C9 substrates, such as aceclofenac, celecoxib, diclofenac, ibuprofen, indomethazine, lornoxicam, meloxicam, naproxen, piroxicam, tenoxicam and valdecoxib.

[PMID 18216720] In a 2008 article (reviewed in [PMID 19422321]) titled "Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding," the study discovered that carriers of CYP2C8*3 (a minor allele of both rs10509681 and rs11572080) had a GI bleeding event risk OR=1.81 (95% CI=0.95–3.46; P=0.071) and risk increased if carriers drank more than 20g alcohol/day to an OR=1.99 (95% CI=1.06–3.74; P=0.034). As CYP2C8*3 and CYP2C9*2 rs1799853 variant alleles are in linkage disequilibrium, patients are likely to carry the risk allele to both 8*3 and 9*2, and when they do, The OR (95% CI) for carriers of such a genotype is increased to 1.94 (1.13–3.33), P=0.017.

[PMID 18216720OA-icon.png] A 2013 NIH review titled "PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8" reiterated that "some data suggest that the combined presence of minor risk alleles CYP2C8*3 (rs10509681 and rs11572080) and CYP2C9*2 rs1799853 is a determinant of NSAID-induced gastrointestinal bleeding." They cited [PMID 18216720].


[PMID 18769365OA-icon.png] Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease.


[PMID 19761371OA-icon.png] Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.


[PMID 20389299OA-icon.png] Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism.


[PMID 20808793OA-icon.png] Are cytochrome P450 CYP2C8 and CYP2C9 polymorphisms associated with ibuprofen response in very preterm infants?


[PMID 21324488] Single nucleotide polymorphisms in tobacco metabolism and DNA repair genes and prognosis in resected non-small-cell lung cancer.



[PMID 23267857] CYP2C19*17 Gain-of-Function Polymorphism Is Associated With Peptic Ulcer Disease


[PMID 23413280OA-icon.png] CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel


[PMID 23420707OA-icon.png] Analysis of the Functional Polymorphism in the Cytochrome P450 CYP2C8 Gene rs11572080 with Regard to Colorectal Cancer Risk


[PMID 23130019OA-icon.png] Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the chilean population: comparison with caucasian and asian populations.


[PMID 23426382] The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARgamma on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes.


ClinVar
Risk Rs10509681(C;C)
Alt Rs10509681(C;C)
Reference Rs10509681(T;T)
Significance Drug-response
Disease rosiglitazone response - Dosage
Variation info
Gene CYP2C8
CLNDBN rosiglitazone response - Dosage
Reversed 0
HGVS NC_000010.10:g.96798749T>C
CLNSRC
CLNACC RCV000417126.1,